Global Injection Pen Market

Injection Pen Market Size, Share, Growth Analysis, By Type(Disposable Injection Pens, Reusable Injection Pens), By Therapy(Diabetes (Insulin, Glucagon-Like Peptide-1), Growth Hormone Therapy, Osteoporosis), By End User(Home Care Settings, Hospitals & Clinics), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2646 | Region: Global | Published Date: October, 2024
Pages: 219 | Tables: 88 | Figures: 66

Injection Pen Market News

  • In July 2024, Sanofi lauded the SoloSTAR 2 as a new design of an insulin pen changing the entire perspective to the functionality of the pen. The insulated flow injector has a simplified dose dial and a larger display. This however, is aimed at the overall user satisfaction with the diabetic patients who use insulin therapy. 
  • In September 2024, Eli Lilly announced its new SmartPen technology, which is meant to be adopted into a digital health ecosystem. This injection pen helps patients in tracking their doses in real-time, and this enables improved interaction with medical practitioners and adjusting treatment regimens for better and effective management of diabetes. 
  • In August 2024, Novo Nordisk introduced its new state-of-the-art insulin injection device, the FlexTouch Smart, which comes with Bluetooth technology. This unique device enables users to download a mobile application which facilitates tracking of dosage and provides reminders in order to help patients easily manage diabetes and comply with their treatment plans.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Injection Pen Market size was valued at USD 45 billion in 2022 and is poised to grow from USD 48.57 billion in 2023 to USD 89.43 billion by 2031, growing at a CAGR of 7.93% during the forecast period (2024-2031).

The competitive landscape of the global injection pen market is characterized by the presence of key players focused on innovation and technological advancements. Global pandemic leading international businesses including Novo nordisk, Sanofi, Boehringer Ingelheim and Pfizer are working on advanced injection pens to improve usability and improve compliance. The aforementioned firms are injecting funds into research and development activities in order to incorporate smart technology and enhance the ergonomic designs of the devices, thereby increasing competition and subsequently fueling the market growth due to the increasing demand for solutions to manage chronic diseases. 'Novo Nordisk A/S (Denmark) ', 'Eli Lilly And Company (US) ', 'Sanofi (France) ', 'Ypsomed Holding AG (Switzerland) ', 'Becton, Dickinson And Company (US) ', 'Merck KGaA (Germany) ', 'AstraZeneca (UK) ', 'Owen Mumford (UK) ', 'Sun Pharmaceutical Industries Ltd (India) ', 'Pfizer Inc. (US) ', 'Biocon (India) ', 'Lupin (India) ', 'Wockhardt Ltd. (India) ', 'Medtronic (US) ', 'Gerresheimer AG (Germany) ', 'Shaily Engineering Plastics Ltd. (India) ', 'SHL Medical AG (Switzerland) ', 'Emperra GmbH E-Health Technologies (Germany) ', 'Nemera France SAS (France) ', 'Jiangsu Delfu Medical Device Co., Ltd. (China) ', 'Solteam Medical (China) ', 'Stevanato Group (Italy) ', 'Wanhai Medical Instruments Co., Ltd. (China)'

The rise in cases of diseases like diabetes, obesity and hormonal deficiencies is one of the key factors giving rise to the demand for injection pens globally. As patients increasingly need to be on treatment constantly, the need for devices for self-administration that are simple to use, accurate and effective continues to increase thereby improving compliance and patient outcomes. 

Rising Adoption of Smart Injection Pens: A notable trend in the global injection pen market is the integration of smart technology. These technologies equipped devices have edge over normal devices by enabling Bluetooth connectivity and compatibility with mobile applications that assists in monitoring the level of medication used by the patients in real time thereby improving patient compliance and enhancing doctor patient communication. 

North America dominates the global injection pen market due to several key factors, including a well-established healthcare infrastructure, high patient awareness, and significant investment in healthcare innovation. The region has a high incidence of chronic illnesses like diabetes and deficiency of growth hormone, which propels the market for self-administration devices. Also, adoption of injectable pens is facilitated by strong reimbursement policies for new medical technologies. Moreover, owing to the presence of numerous global pharmaceutical innovators and constant improvement of pen technology for better patient experience and compliance, North America remains the dominant region in the injection pen market. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Injection Pen Market

Report ID: SQMIG35A2646

$5,300
BUY NOW GET FREE SAMPLE